HIBROW HLTHCARE announced FDA approval for ANDA 215485, a strategic regulatory milestone that advances the company's generic pipeline toward a 2026 delivery. Market analysts are likely to assess the commercial potential of the approved substance, viewing this clearance as a positive sign for future revenue diversification.